0
0
0
s2sdefault

The decision by the Food and Drug Administration (FDA) allowing R.J. Reynolds Tobacco Co. to market e-cigarette products with high nicotine levels is wrong on multiple levels—but the agency’s gravest error is to frame its action as “appropriate for the protection of the public health.” The Premarket Tobacco Product Application pathway requires applicants to provide scientific data that demonstrates a product is appropriate for the protection of public health. In the case of Vuse, the agency found that tobacco-flavored products could benefit addicted adult smokers who switch to these products by reducing their exposure to harmful chemicals due to cigarette consumption.